Kanamycin A Size:Contact [email protected] for quotation InChi: InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17

InChi: InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17

InChiKey: PMKMNTBZJOXTJW-UHFFFAOYSA-N

6)24(34(23)27(22)38)26(37)31-21-10-8-9-18-15-19(35)11-12-20(18)21/h11-12

Golding SE

as well as RSK1 and p70S6K (RSK1: IC50=398 nM

Kanamycin A Size:Contact [email protected] for quotation InChi: InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17Kanamycin A is a broad spectrum antibiotic. Kanamycin A was first isolated in 1957 by Hamao Umezawa from the bacterium Streptomyces kanamyceticus. In vitro: In previous study, kanamycin A was found to block a single cycle of translocation on the poly[U] ribosome, carrying N acetyl diPhe tRNA on the acceptor site and deacylated tRNA at the donor site. The GTPase reaction, catalyzed by EF G and ribosomes, was not significantly affected by kanamycin A.